Boston Scientific Receives Approval for Vercise Deep Brain Stimulation System

Platform offers advanced technology to treat symptoms of Parkinson’s disease

The FDA has approved the Vercise Deep Brain Stimulation (DBS) System (Boston Scientific Corporation) to treat the symptoms of Parkinson’s disease (PD), a degenerative condition that affects more than one million people in the United States and 10 million worldwide. DBS works by stimulating a targeted region of the brain through implanted leads that are powered by a device called an implantable pulse generator (IPG).

The approval was based on the INTREPID study, the first multicenter, prospective, double-blind, randomized sham-controlled study of DBS for PD in the U.S. The INTREPID study evaluated the safety of the system in 292 patients at 23 sites and also evaluated its effectiveness. It successfully met its primary endpoint of mean change in waking hours with good symptom control (n = 160). Data from INTREPID is expected to be released in 2018.

The filing was also supported by safety data from the European multicenter, prospective, single-arm VANTAGE study. In the VANTAGE study, 40 patients treated with the Vercise DBS System demonstrated a 63% improvement in motor function at 52 weeks from baseline as measured by the Unified Parkinson’s Disease Rating Scale III, as well as improvements in quality of life and medication usage.

Following FDA approval, the first commercial implant in the U.S. with the Vercise system will take place at the University of Minnesota Medical Center in Minneapolis by faculty physicians from the University of Minnesota Medical School, including Jerry Vitek, MD, PhD, professor and chair of the Department of Neurology, Michael C. Park, MD, PhD, assistant professor in the Department of Neurosurgery, and Lauren E. Schrock, MD, MnDrive neuromodulation faculty scholar in the Department of Neurology. 

“The Vercise DBS system changes the landscape of what physicians can do to help improve the quality of life for people living with Parkinson’s disease,” said Dr. Vitek, coordinating principal investigator for the INTREPID study. “This system provides an ability to sculpt the current field in the DBS target using novel technology that offers flexibility in programming. This flexibility allows us to target different regions of the subthalamic nucleus, which we believe will improve outcomes while reducing side effects.”

The Vercise system first launched in Europe in 2012 and was developed from a foundation of cochlear implant technology, designed to specifically stimulate auditory nerves to produce a sense of hearing. The Vercise IPG is the smallest rechargeable DBS device available in the U.S. and, depending on individual use, can have a battery life of more than 15 years.

The Vercise system has a proprietary capability that independently controls the amount of current delivered by each of the electrodes on the implanted leads. The Vercise system leads have eight contacts with a long total span of 15.5 mm, tight spacing between each contact of 0.5 mm, and multilumen construction. These system features are designed to work together to address common challenges in DBS therapy, such as fluctuations in symptoms and the progressive nature of the condition, by offering more adaptable delivery of stimulation.

Source: Boston Scientific; December 11, 2017.